CMMB
Chemomab Therapeutics Ltd DRCNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$14.54M
P/E Ratio
—
EPS
$-1.12
Beta
0.51
52W High
$5.77
52W Low
$1.35
50-Day MA
$1.69
200-Day MA
$2.28
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
12.94
PEG Ratio
—
About Chemomab Therapeutics Ltd DRC
Chemomab Therapeutics Ltd. is dedicated to the research and development of biological drugs for the treatment of inflammatory and fibrotic diseases. The company is headquartered in Tel Aviv, Israel.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-7.86M |
| Operating Margin | 0.00% |
| Return on Equity | -70.60% |
| Return on Assets | -40.30% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $1.49 |
| Price-to-Book | 1.35 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | 0.33 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $7.20M |
| Float | $507.78M |
| % Insiders | 11.49% |
| % Institutions | 8.81% |
Historical Volatility
HV 10-Day
89.27%
HV 20-Day
81.15%
HV 30-Day
68.56%
HV 60-Day
84.53%
HV Rank
47.6%
Volatility is currently expanding
Analyst Ratings
Consensus ($15.00 target)
1
Strong Buy1
BuyMore HEALTHCARE Stocks
Data last updated: 5/25/2026